Clarus Therapeutics Holdings Inc

NASDAQ:CRXT  
0.39
-0.01 (-3.34%)
Earnings Announcements

Clarus Therapeutics Reports Fourth Quarter Loss Per Share Of $0.19

Published: 03/30/2022 20:21 GMT
Clarus Therapeutics Holdings Inc (CRXT) - Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results.
Q4 Loss per Share $0.19.
Q4 Revenue Rose 88 Percent to $4.6 Million.
Revenue is expected to be $5.17 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $6.5 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.